Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02683148 · ClinicalTrials.gov registry record · Phase 1
DHEA in Synovial Sarcoma Patients
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02683148 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 11 participants.
The verdict
NCT02683148, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
DHEA is a natural allosteric inhibitor of glucose-6-phosphate dehydrogenase (G6PD). G6PD is a key regulatory enzyme for the survival of synovial sarcoma. The investigators postulate that they can inhibit the production of NADPH in synovial sarcoma and cause cell death by using a naturally occurring G6PD inhibitor.
Interventions
- DRUG DHEA
- OTHER FACT-67 validated survey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-09-13 |
| Est. Completion | 2019-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02683148
The ClinicalTrials.gov registry entry for NCT02683148 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DHEA is the first listed.
NCT02683148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02683148 about?
NCT02683148 is a clinical study titled "DHEA in Synovial Sarcoma Patients". DHEA is a natural allosteric inhibitor of glucose-6-phosphate dehydrogenase (G6PD). G6PD is a key regulatory enzyme for the survival of synovial sarcoma. The investigators postulate that they can inhibit the production of NADPH in synovial sarcoma and cause cell death by using a naturally occurring ...
What is the current status of trial NCT02683148?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2016-09-13. Estimated completion is 2019-04-04.
What interventions are being tested in trial NCT02683148?
The interventions under investigation include: DHEA (DRUG), FACT-67 validated survey (OTHER).
Who is sponsoring clinical trial NCT02683148?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.